Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.14 | N/A | +3.35% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.14 | N/A | +3.35% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They noted solid progress in their product offerings.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to pipeline development.
AbbVie's earnings report shows that the company exceeded expectations on EPS, which positively influenced the stock price, resulting in a 0.85% increase. The lack of revenue data leaves some uncertainty, but management's positive tone suggests they are on the right track with their ongoing projects. Investors may remain cautiously optimistic about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Apr 22, 2019